Matches in Wikidata for { <http://www.wikidata.org/entity/Q59334093> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q59334093 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q59334093 description "wetenschappelijk artikel" @default.
- Q59334093 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q59334093 name "1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study" @default.
- Q59334093 name "1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside" @default.
- Q59334093 type Item @default.
- Q59334093 label "1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study" @default.
- Q59334093 label "1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside" @default.
- Q59334093 prefLabel "1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study" @default.
- Q59334093 prefLabel "1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside" @default.
- Q59334093 P1433 Q59334093-5C4BD7C4-AB7D-4105-974A-008812778219 @default.
- Q59334093 P1476 Q59334093-42786FF5-3705-454D-8F94-B4F291187910 @default.
- Q59334093 P2093 Q59334093-43EE2774-92A6-43E7-950F-A8AB7132A673 @default.
- Q59334093 P2093 Q59334093-5ADD66D8-BEBC-4E4A-A528-65A8E763EC32 @default.
- Q59334093 P2093 Q59334093-6EBA2A2F-1AA6-4230-B0E3-9B158E860D4F @default.
- Q59334093 P2093 Q59334093-EC2BAA3D-51D2-4177-903A-5375B0339DE0 @default.
- Q59334093 P275 Q59334093-e3d4c819-226e-4a9d-9a49-e40b8a66f283 @default.
- Q59334093 P304 Q59334093-48E458AB-4946-4E4B-9B1D-5897D4FD18DA @default.
- Q59334093 P31 Q59334093-E59E1E13-622F-485D-945C-75131196E208 @default.
- Q59334093 P356 Q59334093-FB04F4B7-157F-495F-94DE-C2313783C9DC @default.
- Q59334093 P433 Q59334093-7EC35606-56DB-453F-B46E-9B0954459ED8 @default.
- Q59334093 P478 Q59334093-F9BFAEFB-0888-4007-8C46-5B94FFA45021 @default.
- Q59334093 P577 Q59334093-D3A38ED3-F2B8-4B3B-8874-DF2C3BD7CFA5 @default.
- Q59334093 P6216 Q59334093-6bc8a20c-d172-4bae-8dac-4193f8dbcc95 @default.
- Q59334093 P921 Q59334093-BBA24AC4-5D16-44AE-8FE8-814B6FBA78D1 @default.
- Q59334093 P932 Q59334093-14715A93-9E27-4045-BACD-6DD8667DA33C @default.
- Q59334093 P356 OFY210.1248 @default.
- Q59334093 P1433 Q27725953 @default.
- Q59334093 P1476 "1417. Evaluating the Dissonance Between Cmax and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study" @default.
- Q59334093 P2093 "Christopher M Rubino" @default.
- Q59334093 P2093 "Jason M Pogue" @default.
- Q59334093 P2093 "Nikolas J Onufrak" @default.
- Q59334093 P2093 "Sujata M Bhavnani" @default.
- Q59334093 P275 Q24082749 @default.
- Q59334093 P304 "S437-S437" @default.
- Q59334093 P31 Q13442814 @default.
- Q59334093 P356 "10.1093/OFID/OFY210.1248" @default.
- Q59334093 P433 "suppl_1" @default.
- Q59334093 P478 "5" @default.
- Q59334093 P577 "2018-11-01T00:00:00Z" @default.
- Q59334093 P6216 Q50423863 @default.
- Q59334093 P921 Q31856 @default.
- Q59334093 P932 "6253600" @default.